Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

argenx SE

ARGX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$1,033.15

▼ -1.93%

Market Cap $64.98B · Vol 34.18K

Key Metrics

P/E Ratio

39.25

FWD: 29.92

Market Cap

$64.98B

Large Cap

Div Yield

N/A

EPS Growth

+46.97%

YoY

RSI (14)

60.08

Momentum

Beta

0.44

vs Market

52W High

$1,072.71

3.69% below

52W Low

$662.36

55.98% above

Volume

34.18K

Avg 77.71K

P/B

7.11

Price-to-book

ROE

20.15%

Return on equity

Free Float

99.81%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, argenx SE (ARGX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARGX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.97%

+22.34%

+22.66%

+37.83%

YTD

+22.86%

+40.82%

+101.00%

+194.70%

Financials & Valuation

TTM · Annual

Total Revenue	$4.15B
Net Income	$1.29B
Revenue Growth (YoY)	+59.71%
Gross Margin	89.14%
Operating Margin	25.40%
Net Profit Margin	31.12%
ROE	20.15%
ROA · ROIC	17.18% · 20.08%

P/E Ratio	39.25
Forward P/E (FY1)	29.92
PEG Ratio	0.81
P/S	13.38
P/B	7.11
P/FCF	75.43
EPS Growth	+46.97%
Outstanding Shares	62.56M

Technical Indicators

50-Day SMA	$925.41
200-Day SMA	$844.61
RSI (14)	60.08
Beta	0.44
52-Week High	$1,072.71
52-Week Low	$662.36

Volume Today	34.18K
Avg Daily Volume (30D)	77.71K
Relative Volume	0.44x
Volatility (10D)	31.56
Volatility (30D)	51.71
Free Float	99.81%

Analyst Consensus

BUY

Current Price $1,033.15

Mean Target $1,178.51

52W Low$662.36 52W High$1,072.71

Current

Target

$662.36 $1,072.71

Current Analyst target

+14.07% upside potential · 31 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00GHB88Y8

ISINUS04016X1019

CountryNetherlands

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 30, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00% GMAB Genmab A/S -2.35%

Company Profile

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.